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ABSTRACT
Tetracycline-based inducible systems provide pow-
erful methods for functional studies where gene ex-
pression can be controlled. However, the lack of tight
control of the inducible system, leading to leakiness
and adverse effects caused by undesirable tetracy-
cline dosage requirements, has proven to be a lim-
itation. Here, we report that the combined use of
genome editing tools and last generation Tet-On sys-
tems can resolve these issues. Our principle is based
on precise integration of inducible transcriptional el-
ements (coined PrIITE) targeted to: (i) exons of an en-
dogenous gene of interest (GOI) and (ii) a safe harbor
locus. Using PrIITE cells harboring a GFP reporter or
CDX2 transcription factor, we demonstrate discrete
inducibility of gene expression with complete abro-
gation of leakiness. CDX2 PrIITE cells generated by
this approach uncovered novel CDX2 downstream ef-
fector genes. Our results provide a strategy for char-
acterization of dose-dependent effector functions of
essential genes that require absence of endogenous
gene expression.
INTRODUCTION
Historically, analysis of the molecular genetic mechanisms
underlying cell fate and animal phenotypes has been studied
by abrogating gene function in cellular and animal model
systems. Initially this has been accomplished by random
mutagenesis (1–3), homologous recombination (4) and re-
cently by the use of precise genome editing technologies that
allow for target inactivation of any GOI in cells, tissues and
animal models (5–7). However, the fact that the genetic le-
sions induced are static render these approaches inadequate
in situations where swift reversal of gene function is desired
or in cases where the GOI plays an essential function for
cellular survival. Thus, alternative approaches have to be
employed in these situations. One commonly used alterna-
tive is based on gene ‘knock down’ by RNAi/shRNA (8).
Although the successful application of these technologies
in cell lines is well documented, knock down strategies are
hampered by lack of quantitative and absolute inactivation
of gene function, which makes this approach problematic
in situations where downstream gene functional studies re-
quire complete gene inactivation. In these situations, the use
of inducible gene expression systems has shown to be a pow-
erfulmethodology that allows for: (i) control of gene expres-
sion levels of potentially toxic gene products that could have
adverse side effects on cell growth and survival when ex-
pressed constitutively, (ii) temporal and spatially controlled
activation of genes and proteins and (iii) analysis of cellu-
lar gene dose/response effects. Various inducible gene ex-
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pression systems have been described in the literature based
on cre-lox P system (9), myxovirus resistance 1 promoter
(10), estrogen receptor (11), optogenetics (12), ecdysone-
induciblity (13) or tetracyclin (Tet)-Off/On systems (14–
17). The latter systems are probably the most commonly
used inducible systems for which a plurality of reagents have
been developed, published and are commercially available
(18). However, one disadvantage of Tet-inducible systems
and the majority of the aforementioned inducible systems,
is their well described ‘leakiness’ (19–23). Furthermore, in-
ducible expression in both transient and stable expressing
cells have indicated that cells respond differently to induc-
tion, which has been attributed to heterogeneity in chromo-
somal integration of the inducible gene elements in individ-
ual cells leading to non-homogenous induction responses
(21). Importantly, well known side effects of tetracycline
(and its derivatives) on cell fitness, in particular after long
term treatment, caution for its use in biomedical research
when used at traditional concentrations >100 ng/ml (24–
26).
Thus, there is a yet unmet need in the field to improve
the tightness of the available inducible systems.We reasoned
that the observed ‘leakiness’ with the most commonly used
‘Tet-On’ system (17,27) is due to the uncontrolled random-
ness of integration of the genetic elements encoding both
the ectopically expressed transactivator and the inducible
GOI, leading to muddled inducible gene expression with
pleiotropic downstream effects dependent on the activation
conditions used. Therefore, we hypothesize that by inte-
grating a defined number of transactivator and inducible
transcriptional elements at defined cellular genomic loci we
can (i) circumvent the ‘leakiness’ issue and (ii) lower the
Dox concentration needed for induction below the levels
causing cellular stress. Thus, by taking advantage of pre-
cise genome editing and last generation Tet-On platforms
(18,27), the objectives of this study were to establish a flex-
ible ‘non-leaky’, minimal Dox concentration requiring iso-
genic knockout-rescue system. We built our cellular model
system on the colorectal cell line LS174T and by mono- or
bi-allelic targeting of constitutively expressing transactiva-
tor (Tet3G) elements (TET3G) to one locus and inducible
GFP-reporter elements to another safe harbor locus we
demonstrate minimal Dox requirement, no leakiness and
reversibility of the system. We next demonstrate the util-
ity of the isogenic PrIITE system by mono- or bi-allelic in-
tegration of inducible CDX2 transcription factor elements
into PrIITE cells and re-confirm the reversibility and lack
of leakiness of the system. We also for the first time demon-
strate, that Tet-On leakiness is related to the cellular copy
number of integrated transactivator elements and not the
number of integrated inducible elements of the inducible
system.
Finally we confirm the complete absence in leakiness of
the system by RNA-seq and in combination with ChIP-seq
identify several novel genes directly transcriptionally con-
trolled by CDX2 (Figure 1). The selection of CDX2 as our
target gene was based on its relevance as a key regulator
of intestinal differentiation, with many downstream targets
that can be assessed as read-outs (28).
MATERIALS AND METHODS
ZFN gene targeting plasmids and plasmid donor construction
CDX2 and AAVS1 CompoZr ZFN plasmids for human
CDX2 and AAVS1 were obtained from Sigma targeting
exon 1 of CDX2 (AACTTCGTCAGCCCCccgcagTACCC
GGACTACGGCGGTT) and intron one of the PPP1R12C
gene at theAAVS1 hotspotAAV integration site (ACCCCA
CAGTGGggccacTAGGGACAGGAT), respectively. ZFN
binding sites are shown in upper case and linker cut site
in lower case lettering. ZFNs were tagged with 2A peptide
fused GFP or Crimson as described recently (29). Fluores-
cent protein tagging allows for FACS enrichment and im-
proves efficiency in obtaining correctly targeted clones.
Donor construct was designed based on the previ-
ously described approach by Maresca et al. (30) with the
only modification that inverted ZFN binding sites were
positioned flanking the entire donor insert. A synthetic
ObLiGaRe CDX2 donor vector frame work possess-
ing inverted CDX2 ZFN binding sites (AACCGCCG
TAGTCCGGGTAccgcagGGGGCTGACGAAGTT)
flanking a XhoI/EcoRV linker was generated (EPB64,
Genewiz, USA, Addgene ID#90017). A CMV-Tet3G-
SV40UTR TET3G transactivator encoding fragment
(pTet3G, Clontech/Takara, USA) was XhoI/HindIII
excised (HindIII overhang bluntended) and inserted into
XhoI/XbaI (overhangs bluntended) site of EPB64-donor
vector generating pCDX2-pCMV-TET3G-ObLiGaRe
donor vector.
Various inducible gene expressionObLiGaRe donor con-
structs targeted to the AAVS1 safe harbor locus were
generated based on available AAVS1 safe harbor Com-
pZr ZFN binding element information (Sigma-Aldrich,
USA). A AAVS1 ObLiGaRe donor vector framework was
generated (EPB58, Genewiz, USA, Addgene ID#90016)
and designated pObLiGaRe-AAVS1, possessing the re-
spective inverted ZFN binding elements (5′-atcctgtcccta
ggccacccactgtgggt-3′) flanking an EcoRV multiple cloning
site linker (see Supplementary Figure S11 for vector de-
sign). A full-length codon optimized CDX2 (CDX2opt)
construct was generated (EPB40, GeneArt/ThermoFisher,
USA and SalI/BamHI insert cloned into SalI/BamHI
sites of pTRE3G (Clontech/Takara, USA) generating
pTRE3G-CDX2opt.
A BamHI fragment encoding a Golgi targeted EYFP
fusion protein, T2EYFP (31) was blunt end cloned into
the EcoRV site of pTRE3G generating pTRE3G-T2EYFP.
T2EYFP encodes theN-terminalGolgi targeting and reten-
tion sequence fused to EYFP. The XbaI/XhoI Tet respon-
sive expression fragments from both pTRE3G-CDX2opt
and pTRE3G-T2EYFP were excised and blunt end cloned
into the EcoRV site of pObLiGaRe-AAVS1 (EPB58) gener-
ating pAAVS1-TRE3G-CDX2opt and pAAVS1-TRE3G-
T2EYFP. For pAAVS1-TRE3G-T2EYFP, the donor insert
was excised with PacI/PmeI and inserted into PacI/PmeI
site of a modified AAVS1 targeting vector (EPB71,
Genewiz, USA, Addgene ID#90018) where PacI/PmeI
cloning sites are flanked by insulator sequences and the in-
verted AAVS1 ZFN binding sites. See Supplementary Fig-
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Figure 1. Overview of the established isogenic knockout-rescue model system based on precise integration of inducible elements (PrIITE) in LS174T.
(A) pCDX2-pCMV-TET3G-ObLiGaRe donor vector (pCMV-Tet3G) was targeted to CDX2 exon1 by ZFN mediated targeted integration followed by
pTRE3G-inducible Gene Of Interest (GOI) ObLiGaRe donor vector (pTRE3G-indGOI) targeting to the safe harbor AAVS1 locus. (B) Schematic illus-
tration of the isogenic inducible CDX2 LS174T cell model system based on the mono- (upper panel) or bi- (lower panel) allelic precise genome targeting of
CDX2 inducible elements, CDX2−/−1XindCDX2 and CDX2−/−2XindCDX2 respectively. (C) Illustration of the experimental workflow including deep
transcriptomic analysis (RNA-seq) of wild type LS174T and isogenic indCDX2-PrIITE cells exposed to variable concentrations of doxycycline inducer
and CDX2 target validation by genome-wide CDX2 ChIP-seq (ChIP-seq) analysis.
ure S11 for vector constructs used and generated. All plas-
mids were Sanger sequencing verified.
Cell culture and transfection
LS174T (ATCC-CL-188) human intestinal cell line was
maintained in Ham’s nutrient mixture F12/Dulbecco’s
modified Eagle’s medium (1:1) supplemented with 10% fetal
bovine serum and 1% glutamine. Different target ‘knock in’
strategies were undertaken, including use of 800 bp homol-
ogy arms flanking the donor integration cassette D (data
not shown). Successful LS174T targeted KI was only ob-
tained when the ObLiGaRe strategy for improved target
specific ‘knock in’ integration of donor constructs was em-
ployed (30). In brief, the ObLiGaRe strategy is based on use
of existing ZFNbinding elements that in an ‘inverted’ orien-
tation flank the donor DNA construct. By co-nucleofection
of ZFN’s and donor DNA, double stranded breaks at both
the specific chromosomal target site and flanking the donor
plasmid will occur allowing cellular repair pathway medi-
ated target specific integration of the linearized donor at the
desired target site.
For stable pCDX2-pCMV-TET3G-ObLiGaRe integra-
tion the first exon of the CDX2 gene was targeted through
CDX2 CompoZr ZFNs driven integration (Sigma-Aldrich,
USA) (AACTTCGTCAGCCCCccgcagTACCCGGAC-
TACGGCGGTT, left and right ZFN binding sites capital-
ized and linker cloning site in lower case). 1 × 106 LS174T
cells were transfected by nucleofection, simultaneously
with the GFP/E2 Crimson tagged CDX2 ZFN plasmids (2
g each) and the pCDX2-CMV-TET3G-donor vector (5
g). Nucleofector solution T (Lonza, CH)/Nucleofector
program T-020 were used for the electroporation procedure
in an Amaxa Cell Line Nucleofector device (Lonza, CH).
Cells were then cultured for 6 h at 37◦C to stabilize, and
then moved on to a 30◦C cold shock. Two days after
transfection, cells expressing both GFP and E2 Crimson
were sorted out in a FACS ARIA III (BD BioSciences,
USA) as previously described (29). The cell bulk was plated
out to grow in collagen-coated plates and two rounds of
cloning were then employed.
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Single cell clones were screened by junction PCR using a
primer flanking the 5′ CDX2 target locus and a reverse ori-
ented primer localized within the integrated pCMV-TET3G
cassette (Supplementary Figure S1A and B). Based on
IDAA assay (32), one of them (5B5) showed the presence
of wt allele, representing heterozygozity for pCMV-TET3G
integration at the CDX2 locus (clone named LSCDX2+/−),
while the other two clones (3D6 and 5E2) were found to
possess successfully integrated pCMV-TET3G transactiva-
tor at both alleles representing homozygozity for pCMV-
TET3G (clones named LSCDX2-/−#1 and LSCDX2-/−#2 re-
spectively).
1 × 106 cells from a CDX2 KO clone containing mono
or bi-allelic pCMV-TET3G transactivator inserted into the
two CDX2 alleles were then transfected by nucleofection
with GFP/E2 Crimson tagged AAVS1 ZFN plasmids (2 g
each) and 5 g pAAVS1-TRE3G-CDX2opt or pAAVS1-
TRE3G-T2EYFP.
Clone characterization by polymerase chain reaction (PCR)
and IDAA
In order to identify correct integration of pCDX2-CMV-
TET3G, a region comprising a part of CDX2 exon 1 up-
stream the ZFNs cutting site and left 800 bp homology arm
and a part of the CMV promoter was amplified using Ex-
pand Long Template PCR System (Roche Applied Science,
GE) (5′-CMV-TET3G junction PCR). Similarly, the identi-
fication of correctly integrated pAAVS1-TRE3G-CDX2opt
or pAAVS1-TRE3G-T2EYFP fragments intoAAVS1 locus
was performed by amplification of a region comprising a
part of AAVS1 upstream the ZFNs cutting site and a part
of the TRE promoter (5′-TRE3G-CDX2opt or TRE3G-
T2EYFP junction PCR). PCR reaction mixture consisted
of 100 ngDNA, 2.5l buffer 1, 3.0l 1.25mMdNTPsmix,
0.25 l each primer at a concentration of 25 M, 0.1 l en-
zyme mix and water to a final volume of 25 l. All junction
PCR primers were obtained from TAG Copenhagen A/S,
Denmark and are listed in Supplementary Table SIV. Am-
plification was done using the following touch down proto-
col. After preheating for 5 min at 95◦C, 12 cycles were per-
formed starting with denaturation for 45 s at 95◦C, anneal-
ing for 15 s at 74◦Cwith a decrease in annealing temperature
of –1◦C/cycle, and 2 min at 72◦C, followed by an additional
25 cycles of 45 s at 95◦C, 15 s at 64◦C and 2 min at 72◦C,
followed by a final extension of 3 min at 72◦C. PCR prod-
ucts were run in a 1.2% agarose gel, bands were gel purified
and sequence confirmed by Sanger sequencing.
FACS-enriched stable clones (29) were screened by junc-
tion PCR using primers flanking the junction between the
CDX2 orAAVS1 genes and the integrated cassette (Supple-
mentary Figures S1 and S2).
Presence of unmodified CDX2 or AAVS1 target (WT
allele presence test) was performed using the recently de-
scribed IDAA method (32) and protocol guidelines (33).
In brief, due to size of the donor constructs used (>2 kb,
respectively) the respective CDX2 or AAVS1 ZFN target
sites can only be successfully amplified if integration has
not occurred at the respective target loci. PCR was per-
formed using 100 ng DNA in 25 l using AmpliTaq Gold
(ABI/Life Technologies) for CDX2 locus or TEMPase Hot
Start DNA Polymerase (Ampliqon A/S, DK) for AAVS1
locus using the recently described IDAA/tri-primer ampli-
fication conditions comprising primers flanking the respec-
tive target site in combination with a universal 6-FAM 5′-
labeled primer (FamF), specific for a 5′-overhang attached
to the forward primer. IDAA primers used were purchased
from TAG Copenhagen A/S and are listed in Supplemen-
tary Table SIV. Fluorescently labeled amplicons were then
analyzed by capillary electrophoresis based fragment analy-
sis using an ABI3030 instrument (Applied Biosystems/Life
Technologies, USA). Raw data obtained was analyzed us-
ing Peak Scanner Software V1.0 (Applied Biosystems/Life
Technologies, USA).
Induction with Dox
The Tet-On3G system was induced with Dox (Sigma-
Aldrich, USA) in a range between 0.004 and 4 g/ml
for CDX2 knock-in (KI) clones and 0.001–5 g/ml for
T2EYFP KI clones. Dox was added to the medium every
24 h for one or 2 days, and medium was exchanged every 48
h after Dox removal. Controls where Dox was not added to
the medium were used (0 g/ml of Dox).
Western blot of cell lysates
Whole-cell extracts were obtained by resuspension of cell
pellets in RIPA buffer (50 mM Tris–HCl pH 7.4, 150 mM
NaCl, 2 mM EDTA, 1% NP-40, 0.1% sodium dodecyl sul-
phate) in the presence of complete protease inhibitors cock-
tail (Roche Applied Science, GE). Quantification of total
protein was determined by bicinchoninic acid protein assay
(Thermo Scientific™ Pierce, USA). 15g of protein extracts
were then analyzed by standard SDS-PAGE, transferred to
a nitrocellulose membrane (GE Healthcare Life Sciences,
USA) and blotted on at 4◦C with mouse monoclonal pri-
mary antibodies CDX2-88 1:500 (Biogenex, USA), anti-
TetR 1:1000 (Clontech/Takara, USA), anti-MUC2, undi-
luted hybridoma supernatant and anti-actin 1:8000 (Santa
Cruz Biotechnology, USA) in 5% BSA in PBS. Mem-
branes designed forMUC2 blotting were previously treated
with neuraminidase from Clostridium perfringens type VI
(Sigma-Aldrich, USA) diluted in PBS to a final concentra-
tion of 0.2 U/ml, for 1 h at 37◦C. Peroxidase-conjugated
secondary antibodies (goat polyclonal anti-mouse-HRP
1:2000 for CDX2, TetR and MUC2 and goat polyclonal
anti-rabbit-HRP 1:2000 for actin (Santa Cruz Biotechnol-
ogy, USA) were used and developed with the ECL detection
kit (Bio-Rad Laboratories, USA).
RNA extraction
Total RNA was extracted using RNeasy kit (Qiagen, GE)
as recommended by the manufacturer.
Transcriptomics (RNA-Seq)
Polyadenylated RNA was isolated from total RNA using
standard protocols (Dynabeads mRNA Direct Micro Kit,
Ambion/Life Technologies, USA) starting with 5 g total
RNA. Library preparation forNGS using Ion Torrent tech-
nology (Life Technologies, USA) was carried out according
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to the manufacturers recommendations (Ion Total RNA-
Seq Kit v2, Ion torrent/Life Technologies, USA), and se-
quenced using an Ion Proton system (Life Technologies,
USA). Quality control, quantification of RNA and libraries
was carried out using using Agilent RNA 6000 Nano Kit
or Agilent High Sensitivity DNA kit and Agilent Bioana-
lyzer (Agilent Technologies, USA). Sequencing reads were
mapped to hg19 and bioinformatics analysis was conducted
using CLCs Genomic Workbench (CLC bio/Qiagen, DK),
STARBowtie2 followed by Cufflinks for expression anal-
yses. In brief, ∼50 ng polyA RNA was fragmented down
to 100–300 base fragments using RNaseIII for 1–3 min fol-
lowed by adapter ligation, amplification for 9–14 cycles and
barcoding using Ion Express RNA-Seq Barcode kit (Ion
Torrent/Life Technologies, USA). The final library frag-
ment size and concentration was determined by Agilent
Bioanalyzer analysis followed by template preparation us-
ing Ion PI Template OT2 200 Kit v3 (Life Technologies,
USA) and Ion One Touch System followed by NGS on an
Ion Proton system using Ion PI™ Chip Kit v2. In general,
two transcriptome libraries were barcoded and analyzed on
one Ion PI v2 chip. Sequencing depth for the RNA-Seq
data sets ranged from 34.5 to 44.6 mill reads/sample with
95.4–97.7%mappable reads to the hg19 reference data base.
Mean read length for transcriptome RNA-Seq data ranged
from 116 to 136 bp.
Genome-wide analysis of CDX2-binding sites by ChIP-seq.
LS174T cells grown for five days in a 30 × 30 cm cul-
ture dish were cross-linking and sonicated as described pre-
viously to generate fragments of ∼0.2 to 1.2 kb. Here-
after, the ChIP-protocol was performed as previously re-
ported (34). Briefly, immunoprecipitation was done in
four replicates and performed overnight at 4◦C using spe-
cific antibodies to human CDX2 (CDX2-88, Biogenex,
USA) and the influenza hemagglutinin (HA) epitope (rab-
bit polyclonal -HA; Santa Cruz Biotechnology Inc, Hei-
delberg, Germany), used as a negative control. Immuno-
complexes were recovered with 50 l protein A/G beads
(Invitrogen/ThermoFisher Scientific, USA). Verification of
the enrichment in the CDX2-immunoprecipitated DNA
samples was done by qPCR analyzing the DNA level from
known CDX2-targets in the CDX2-immunoprecipitated
samples and comparison it to level in the negative control
(HA-immunoprecipitated DNA).
In order to increase the depth of the analysis, the ChIP
library established was deep sequenced using Ion Proton in-
strumentation generating an approximate≈54million reads
depth. Library preparation for NGS was carried out with
the Ion Xpress Plus gDNA Fragment Library Kit accord-
ing to User Bulletin 4473623: Ion Chipseq Library Prepa-
ration on the Ion Proton System (Life Technologies, USA),
starting with 10 ng DNA. Quality control of the libraries
was carried out using using Experion DNA 1K analysis
kit and the Experion System (Bio-Rad Laboratories, USA).
In brief, 10 ng DNA was end-repaired and ligated to bar-
code adaptors from the Ion Xpress Barcode Adapters 1–
16 Kit (Life Technologies, USA), followed by nick repair
and amplification for 18 cycles. The amplified libraries were
subjected to two rounds of bead capture with the Agen-
court AMPure XP Kit (Beckman Coulter, USA) to size-
select fragments ∼160–340 bp in length. The final library
concentration was determined by Qubit analysis (Ther-
moFisher Scientific, USA). The barcoded ChIP- and IP
control-DNA-libraries were handled similarly to the RNA-
Seq library and analyzed on a single Ion PI™ Chip v2. For
the ChIP- and IP control-DNA-libraries a total of 54.5 mill
reads (21.8 and 32.7 mill respectively) were obtained and
98.5% were mappable to the reference hg19 data base with
a mean read length of 130 bp. The detection of CDX2 ChIP
seq peaks and the location of the closest genewas performed
using CisGenome version 2 (35).
Immunodetection by fluorescence-activated cell-scanning
(FACS) analysis
Cells were trypsinized at different time-points after induc-
tion with Dox or after Dox removal and washed twice
with PBS. After being centrifuged at 1200 rpm for 7 min,
CDX2 KI cells were fixed in 4% PFA for 20 min., washed
in PBS and permeabilized in cold methanol for 15 min. Af-
ter washing with PBS, samples were incubated with the pri-
mary antibody (CDX2-88 clone, BioGenex, 1:500.) for 1
h at 37◦C. Cells were then stained with FITC-conjugated
AfinityPure immunoglobulin antimouse IgG (Jackson Im-
munoResearch Laboratories, USA) diluted 1:100 in 0.05%
BSA in PBS and then subjected to FACS in a FACS ARIA
III (BD BioSciences, USA). T2EYFP KI cells were imme-
diately scanned by FACS after cell trypsinization.
Immunocytochemistry
Cell slides were fixed in cold acetone for 15 min. For TetR
anti-TetR cells were incubated overnight at 4◦C with the
primary antibodies (9G9 clone, Clontech/Takara, USA).
Negative controls were performed by omission of primary
antibodies. After washing, a rabbit anti-mouse Ig FITC-
labeled secondary antibody (Dako A/S, DK) diluted 1:100
in PBS with 5% BSA was added for 45 min, protected from
light. DAPI was used as a nuclear counterstain and slides
weremounted in Vectashieldmountingmedia (Vector Labs,
USA).
For EYFP visualization on the induced T2EYFP KI
clones, trypsinized cells were fixed in cold acetone for 10
min, DAPI was added and slides mounted. Samples were
examined under a Zeiss fluorescence microscope equipped
with DAPI and FITC interference filters. Images were ac-
quired using a Zeiss Axioskop 2 and an AxioCam MR3
camera and Zeiss Application Suit software.
Real time in vivo video material
For the time lapse video, 1 × 106 CDX2−/−2XindT2EYFP
cells were seeded in a well of a six-well plate and 0.5 g/ml
of Dox were added after 24 h. Time lapse images started to
be acquired under dark field immediately after Dox addi-
tion and every 20 min during 24 h using a Leica DMI 6000
timelapse microscope equipped with FITC interference fil-
ter and with CO2 supply.
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RESULTS
Precise integration of inducible transcriptional elements (PrI-
ITE)
CDX2 knock-out by targeted integration of Tet3G transac-
tivator elements. In order to eliminate the adverse cellular
effects seen from prolonged exposure to Dox (25,26), we de-
signed a strategy combining stable and controlled TeT-On
transactivator/TeT3G expression with disruption of a tar-
get gene. First we established a Tet3G expressing LS174T
cell line, in which the TET3G elements were targeted to
CDX2 exon1 CDS, thereby abrogating the endogenous gene
function. Targeting CDX2, a master differentiation tran-
scription factor (36), allowed us to determine the efficacy
of the system in an unprecedented CDX2 knock out cell
system (Figure 1). Multiple attempts at homologous re-
combination driven donor integration at the CDX2 exon
1 locus based on CDX2 ZFNs and a TET3G donor tem-
plate flanked by 700bp homology arms did not give rise
to any correctly targeted clones, likely due to low homolo-
gous repair capacity of LS174T cells used in this study (data
not shown). pCDX2-pCMV-TET3G-ObLiGaRe donor vec-
tor (Figure 1A and Supplementary Figure S1A) was co-
transfected together with CDX2 CompoZr ZFN plasmids
into LS174T cells, whereby pCMV-TET3G transactiva-
tor donor vector was specifically integrated into exon1 of
CDX2, as illustrated in Figure 1A and Supplementary Fig-
ure S1A and B, by ObLiGaRe driven recombination (see
Material and Methods section for details). Three clones
(5E2, 3D6 and 5B5) were shown to include correct inte-
gration of the pCMV-TET3G construct and constitutively
express the Tet3G transactivator (Supplementary Figure
S1C), one clone, 5B5, was mono allelically targeted (des-
ignated LSCDX2+/−) and CDX2 protein expression main-
tained at levels similar to the parental LS174T wt cell line
and in the bi-allelic targeted CDX2 knock-out (KO) clones,
3D6 (LSCDX2−/−#1) and, 5E2 (LSCDX2−/−#2), CDX2 ex-
pression was completely abrogated (Supplementary Figure
S1C and D). Constitutive Tet3G expression and abrogation
of CDX2 was maintained after prolonged cell passaging
and after freeze/thawing lack of CDX2 was correlated with
significantly decreased protein levels of a well-know CDX2
target gene, MUC2 (37) (Supplementary Figure S1C and
D). Lastly, we tested the functionality of the mono and bi–
allelically targeted CDX2 KO cells by cellular transfection
with known CDX2 enhancer reporter constructs and could
show dose dependent decreased expression of aHNF4A re-
porter and >10-fold reduced expression of a HEPH1 re-
porter (38) in the CDX2 KO cells (Supplementary Figure
S3).
We thus show, thatCDX2KO by ZFN-mediated site spe-
cific pCMV-TET3G integration in LS174T cells was effec-
tively accomplished and that stable Tet3G expression was
maintained over time.
Safe harbor targeted integration of inducible T2EYFP ele-
ments. Having shown that both LSCDX2-/−#1 and #2 dis-
play similar transactivator expression levels, an inducible
T2EYFP model system was established in LSCDX2−/−#1.
The inducible pTRE3G-T2EYFP-ObLiGaRe donor vec-
tor was targeted to the safe harbor AAVS1 locus by
co-transfection with AAVS1 CompoZr ZFN’s into the
LSCDX2−/−#1 cells as illustrated in Figure 2A. Multiple
correctly targeted indT2EYFP clones were obtained and
two of these selected for further detailed analysis, one
mono-allelic T2EYFP targeted clone 7E9 (hence forward
referred to as CDX2−/−1XindT2EYFP) and another bi-
allelic targeted clone 5G8 (henceforward referred to as
CDX2−/−2XindT2EYFP), Supplementary Figure S2. Both
clones maintained constitutive Tet3G expression and ab-
sence of CDX2 (Figure 2B).
LS174T indT2EYFP PrIITE cells display no leakiness and
Dox induction is fast and reversible.. We first aimed to de-
termine the leakiness of the inducible T2EYFP reporter in
the CDX2−/−1xindT2EYFP and CDX2−/−2xindT2EYFP
clones by FACS and immunofluorescence, which showed
undetectable fluorescence in uninduced PrIITE cells (Fig-
ure 2C, D and E). Upon induction, immunofluorescence
displayed the expected peri-nuclear reactivity, consistent
with the correct sub-cellular localization of T2EYFP fusion
protein in the Golgi apparatus (39) (Figure 2E).
We next determined the induction dynamics over time
by in vivo live imaging, demonstrating that the induc-
tion dynamics is very rapid. T2EYFP expression is de-
tectable within 4 h post induction and all cells display
full expression of the reporter after 8–10 h (Supplemen-
tary video material). Importantly, the induction dynam-
ics is fully synchronized and all cells simultaneously be-
come positive for the T2EYFP reporter. To elucidate how
Dox dosage might influence on the dynamics of the sys-
tem, induction was performed using variable Dox concen-
trations ranging from 0 to 5 g/ml. As shown in Figure
2C, modest induction was observed with dox concentra-
tions<5 ng/ml, whereas significant induction requiredDox
concentration >10 ng/ml. Interestingly, these results sug-
gest, that the induction potential is related to the number
of inducible elements integrated into the system. For in-
stance, using a 10 ng/ml Dox dosage rendered >90% of
the CDX2−/−2XindT2EYFP cells EYFP reporter positive,
whereas <50% CDX2−/−1xindT2EYFP cells were found
positive for this dosage.
Next, the reversibility of the PrIITE cell systemwas quan-
tified by FACS analysis of the EYFP expressing cell popu-
lation after Dox removal from the media (Figure 2D). As
observed, induction was fully reversible and after 10 days
post Dox removal, all cells in the population returned to
non-expressing levels. However, the dynamics in reversibil-
ity was found to be dependent on both number of inducible
elements integrated and the Dox dosage used. Clearly re-
versal to non-expressing levels was achieved rapidly and
within 5 days for CDX2−/−1XindT2EYFP and slower for
CDX2−/−2xindT2EYFP using the lower 50 ng/ml induc-
tion dosage.
We thus demonstrate that the PrIITE cell system displays
no leakiness, is fully reversible, and that the induction dy-
namics occurs fast and in a synchronized manner and re-
quire below cellular stress inducing Dox concentrations.
LS174T indCDX2 PrIITE cells show no leakiness and ec-
topic CDX2 expression is tightly controlled requiring min-
imal Dox induction levels. The role of CDX2 in intesti-
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Figure 2. Overview of the proof of principle system using inducible T2EYFP reporter in isogenic LS174T-PrIITE cells. (A) First pCMV-Tet3G was tar-
geted to CDX2 exon1 of LS174T cells generating mono- or bi-allelic CDX2 KO cells, CDX2+/− and CDX2−/− respectively. Next, cells were re-targeted
with pTRE3G-T2EYFP ObLiGaRe-donor vector (pTRE3G-T2EYFP) directed to the safe harbor AAVS1 locus generating CDX2−/−1XindT2EYFP and
CDX2−/−2XindT2EYFP cells. (B) Western blot analysis of LS174wt, CDX2−/−, CDX2−/−1XindT2EYFP and CDX2−/−2XindT2EYFP cells show ab-
sence of CDX2 and stable TeT3G expression. (C) FACS based determination of percentage indT2EYFP positive cells after induction with different Dox
concentrations. The graph shows that induction is dose and copy number dependent in CDX2−/−1XindT2EYFP and CDX2−/−2XindT2EYFP PrIITE
cells. Approximate 100% T2EYFP positive cells was achieved using >0.005 g/ml Dox concentration for CDX2−/−2XindT2EYFP. Maximum 70% posi-
tivity was achieved regardless of the higher Dox induction concentrations used for CDX2−/−1XindT2EYFP cells. Importantly, CDX2−/−2XindT2EYFP
cells show complete absence in T2EYFP fluorescence in uninduced cells thus, no leakiness of T2EYFP LS-PrIITE cells was detectable. Critical dox concen-
tration above which adverse cellular stress (24–26) is caused is indicated by a dotted gray line. (D) Reversibility of induction as determined by FACS analysis
of fixed cells 1, 5 or 10 days post 48 h induction with variable Dox induction concentrations. Notably, reversibility was copy number and dox dependent
and full reversibility within 10 days was only achieved for CDX2−/−1XindT2EYFP PrIITE cells using the lower 0.05 g/ml Dox concentration. (E) Sub
cellular localization of inducible T2EYFP as determined by fluorescence of fixed trypsinized indCDX2 PrIITE cells with or without dox induction. Arrow
heads indicate expected Golgi localization of T2EYFP.
nal gene regulation is well known. However, to the best
of our knowledge no studies so far described the effect of
complete ablation of CDX2 from the cellular genome. In
a single study CDX2 has been suggested as a lineage sur-
vival oncogene when amplified in colorectal cancer (40).
In order to distinguish endogenous from ectopically ex-
pressed CDX2 transcripts the inducible CDX2 open read-
ing frame was codon optimized (hereafter referred to as in-
dCDX2). pTRE3G-indCDX2-ObLiGaRe donor vector was
targeted to the AAVS1 safe harbor site of LSCDX2-/−#1
cells generating clones 7D9 (CDX2−/−1XindCDX2) and
6D6 (CDX2−/−2XindCDX2) possessing one or two in-
ducible codon optimized CDX2 copies respectively (Fig-
ure 1B and Supplementary Figure S4). Constitutive
Tet3G expression was maintained in targeted cells and
CDX2−/−2XindCDX2 or CDX2−/−1XindCDX2 cell in-
duction dynamics over 24 h were similar (Figure 3A and
B). To test the reversibility of the CDX2 PrIITE sys-
tem built, we induced with a range of Dox concentra-
tions (0–4 g/ml) for 48 h followed by removal of Dox
from the medium. As expected, no expression of indCDX2
was revealed in non-induced cells followed by fast dose
dependent Dox induction dynamics (Figure 3C). Impor-
tantly, for the lowest concentration of Dox used (0.004
g/ml), the induction dynamics for the CDX2−/− 1Xind-
CDX2 clone was slower than for CDX2−/−2XindCDX2
(Figure 3C). Of notice, the indCDX2 protein levels,
reached for CDX2−/−1XindCDX2 with 4 ng/ml Dox dose,
were similar to the endogenous CDX2 levels detected
in LS174Twt cells (Supplementary Figure S4E) while for
CDX2−/−2XindCDX2 induction reached 120× higher lev-
els relative to LS174Twt levels (Supplementary Figure S4E).
In contrast to the dynamics in reversibility for indT2EYFP
KI clones (Figure 2), reversibility of indCDX2 induction
appeared faster and required very modest Dox induction
dosages in the sub cell stress inducing nanogram/ml range.
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Figure 3. Induction dynamics of isogenic inducible CDX2 LS174T PrIITE cells. (A) Anti-TeT3G transactivator immunofluorescence in
CDX2−/−2XindCDX2 cells and not in LS174T wt cells. (B) 24 h induction kinetics of indCDX2 using different Dox concentrations. >60% of
CDX2−/−1XindCDX2 and CDX2−/−2Xind CDX2 cells become indCDX2 positive after 24 h 0.004 g/ml Dox induction. Use of higher Dox con-
centrations higher percentage of cells become CDX2 positive after 24 h Dox treatment. (C) Dynamics in reversibility of the PrIITE system using different
Dox induction concentrations. CDX2−/−2Xind CDX2 (left panel) and CDX2−/−1Xind CDX2 (right panel) cells were induced 48 h with the Dox con-
centrations indicated above the panels. Hereafter Dox was removed and post induction indCDX2 protein levels were determined by Western blot analysis
1, 3, 5 or 8 days post Dox removal. Maximum indCDX2 induction levels were achieved using 0.004 g/ml Dox concentration for CDX2−/−2XindCDX2
whereas 0.040 g/ml Dox was required for CDX2−/−1Xind CDX2.
Based on western blot analysis indCDX2 protein was un-
detectable within 3 days post Dox removal for both mono-
and bi-allelic clones (Figure 3C).
Validating the tightness in inducibility of the PrIITE by
deep transcriptome analysis. To confirm the tightness of
the PrIITE system and in order to determine the CDX2
downstream target genes, LS174Twt, uninduced and in-
duced CDX2−/−2XindCDX2 or CDX2−/−1XindCDX2
cells were RNA-seq transcriptome profiled (Figure 4A, and
Supplementary Figure S5). To ensure that the isogenic PrI-
ITE cells generated were representative of the mosaic mod-
erately well differentiated LS174Twt cell population (41), all
comparative analysis here and in the following sections in-
cluded LS174Twt cells. Approximately 10 000 genes with
RPKM >1 were shown to be expressed in the wt cells
and the expression profiles for the mucin genes MUC2
and MUC5AC correspond to the profiles previously re-
ported for LS174Twt cells with high expression for the for-
mer and low expression for the latter (42,43) (Figure 5B).
CDX2 target genes were defined by the following crite-
ria; genes with RPKM >1 in wt cells where RPKM values
in uninduced PrIITE cells (CDX2−/−) were reduced >4×
(4×↓) and increased >2× (2×↑) after re-induction rela-
tively to the uninduced RPKM values. In depth analysis
of the RNASeq reads that mapped to the human exon1
CDX2 gene locus, including the region across the CDX2
ZFNs cutting site, confirmed the presence of out of frame
transcripts possessing deletions in CDX2−/−2XindCDX2
exon1, while the heterozygous CDX2−/−1XindCDX2 clone
expressed intact endogenous CDX2 transcripts present at
≈40% of the LS174Twt transcript levels (Supplementary
Figure S5A). Analysis of the unmapped RNA-seq reads
confirmed the presence of the Tet3G transactivator tran-
scripts in CDX2−/− cells (Supplementary Figure S5B) and
importantly, no indCDX2 transcript was detected in the
uninduced state of the CDX2−/−2XindCDX2 clone (Sup-
plementary Figure S5B), thus confirming the biochemical
and immunofluorescence results obtained previously.
Taken together, by biochemical analysis, immunofluores-
cence and deep transcriptome analysis, we have shown that
the PrIITE system allows for absolute control of inducible
and reversible gene expression of CDX2 and it’s down-
stream target genes.
Validating the transcriptome identified CDX2 target genes by
genome-wideChIP-seq analysis. Reasoning that theRNA-
seq identified CDX2 target genes could be direct or indirect
targets of CDX2, we wanted to validate the RNA-seq data
set by genome wide chromatin immunoprecipitation se-
quence analysis (ChIP-seq).We thus used ChIP-seq to iden-
tify trueCDX2binding elements in the vicinity of theRNA-
seq identified CDX2 target genes. ChIP was performed on
LS174Twt cells using a well-known anti-CDX2monoclonal
antibody essentially using a previously reported procedure
(38). A LS174T non-immunoprecipitated library was deep
sequenced in parallel and used as ChIP-seq background
control. An additional requirement was added to the RNA-
seq criteria for positive scoring of primary CDX2 target
genes, in that a ChIP-seq peak (CDX2 binding element)
were to be present within or 1 kb up or downstream of
the target gene. The combined RNA- and ChIP-seq cri-
terion identified 31 direct CDX2 target genes (Figure 4B
and Supplementary Table SI). Among these genes several
known CDX2 regulated targets were found, such as TFF3,
MUC2 and CDX2 itself, but several novel targets were also
found, including MUC5B, MUC5AC, MUC6, GPA33 and
LDLR (Figure 5). Furthermore, in vitro promotor analysis
confirmed the CDX2 dependent regulation of the enhancer
identified in the novel CDX2 target gene GPA33 (44) (Fig-
ure 6) and thus, substantiated both our RNA- and ChIP-
seq findings. Interestingly, a significant intergenic CDX2
binding element was identified in the 300 Mb 11p15 re-
gion containing the mucin genes MUC6, MUC2, MUC5B
and MUC5AC (Supplementary Figure S6A). Clearly our
transcriptome results reveal a significant concerted down-
regulation of this gene cluster and suggest CDX2 as a ‘lo-
cus control gene’ (Figure 5B). As expected, the non CDX2
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Figure 4. Deep RNA-seq and genome wide ChIP-seq analysis of LS174Twt and induced or uninduced CDX2−/−2XindCDX2 PrIITE cells. (A) Of the
20 327 human genes included in the analysis around 9965 were found to be expressed with RPKM >1, the majority hereof (7346) were low expressed
genes with 1 < RPKM < 10 (A), followed by medium expressed genes (1847) with 10 < RPKM < 50 (B) and highly expressed genes (772) with 50 <
RPKM (C). In uninduced CDX2−/−2XindCDX2 (−Dox) PrIITE cells (lacking CDX2), 712 genes expressed in LS174Twt were 4-fold down regulated
and after indCDX2 re-induction (+Dox) 349 of these genes were 2-fold upregulated and thus suggested to be CDX2 downstream target genes. (B) In
order to determine to what degree the genes identified represent direct CDX2 target genes, we included a LS174T ChIP-seq data set and seeked for the
presence of potential CDX2 regulatory elements in the vicinity of the RNA-seq suggested CDX2 target genes. Inclusion of this criteria (numbers shown
in parenthesis) in addition to the RNA-seq criterion defined above resulted in a dramatic decrease in potential direct CDX2 targets going from 349 to 31
genes. The expanded view at right depicts the number of targets identified using the RNA-seq or RNA-seq+ChIP-seq criteria. In the latter case the targets
indicated below the stippled line are listed in Supplementary Table SI.
regulated mucin genes MUC1 and MUC7 did not possess
any CDX2 binding elements and did not respond to CDX2
changes (Figure 5B and Supplementary Figure S6B). Previ-
ously, we have identified CDX2 as a regulator of glycosyl-
transferase encoded ST6GALNAC1 expression (45). How-
ever, in this study, no CDX2 binding elements were iden-
tified in the ST6GALNAC1 locus (Supplementary Figure
S6B), which suggests that CDX2 regulates the expression
of this gene by an indirect effect.
The results also show that several known CDX2 tar-
gets such as FUT2 (46), B3GALT5 (47), ALP1 (48) and SI
(28) in LSCDX2 PrIITE cells were unaffected by CDX2
changes (Figure 5B and Supplementary Figure S7) and no-
tably, in the latter three cases these genes were shown not to
be expressed in LS174Twt cells. Of notice, the only glyco-
genes (49) otherwise affected by CDX2 were FUT3 and
GALNT1 which in the latter case responded inversely to
CDX2 changes (Figure 5B).
In order to assess to what degree the global reversibil-
ity in gene expression for LSCDX2 PrIITE cells was re-
tained, RPKM values from LS174Twt and LSCDX2 PrI-
ITE cells exposed to different Dox concentrations ranging
from 0 to 40 ng/ml were plotted and the regression line for
each data calculated (Figure 7 and Supplementary Figure
S8). The results show that global reversibility of CDX2 con-
trolled gene expression was profound, and in many cases
full reversibility was observed when the lowest 4 ng/ml
Dox concentration was used with CDX2−/−2XindCDX2
cells. Clearly, the combined RNA-seq and ChIPseq filter-
ing strategy employed improved the specificity in defining
true CDX2 regulated genes in our data set (Figure 7C). We
speculate, that the observed highest normalization levels of
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Figure 5. CDX2 regulated target genes. (A) Based on the includedRNA-seq andChIPseq criteria (see Figure 4 and Supplementary Table SI) top 10 primary
targets downstream of CDX2 with most abundant transcripts (highest RPKM values) were ranked. Well known CDX2 target genes were identified such
as TFF3 andMUC2, but novel targets were also identified including GPA33 and LDLR. (B) Careful analysis of 208 glycogenes (49) controlling the cellular
glycophenotype and 23 mucin genes revealed that MUC5B, MUC6 and MUC5AC were controlled by CDX2, whereas MUC1 and MUC7 did show no
correlation with CDX2 expression. No CDX2 correlation with FUT2 and B3GALT5 could be demonstrated, which is in contrast with previous reports.
On the other hand, ST6GALNACI and -VI were shown to correlate with CDX2 expression although no CDX2 binding element could be identified within
the vicinity of the CDS of these genes. Interestingly, an inverse correlation was observed for GALNT1 regulation similar to SOX2 (see Supplementary
Figure S7), with upregulation in the absence of CDX2 expression. Interestingly, the novel CDX2 target GPA33 gene product has been shown to be post
translationally modified by the GALNT1 encoded enzyme. Genes with ChIP-seq identified CDX2 binding elements in the gene locus vicinity are indicated
by an *.
re-induced CDX2 for 4 ng/ml Dox may be due to the role
of CDX2 as a molecular rheostat potentially controlling: (i)
self-renewal as indicated in Figure 5 and/or (ii) regulated
expression of downstream target genes within discrete and
narrow CDX2 expression limits (50). Lastly, in order to de-
termine if the genetic manipulations had changed the dif-
ferentiation state and stemness of CDX2 PrIITE cells gen-
erated, we determined the expression profile of 24 marker
genes before and after genetic manipulation and/or CDX2
re-induction (Supplementary Figure S7). In all cases (ex-
cept forMUC6), the gene expression profiles of genetically
manipulated cells relative to LS174Twt was retained and
displayed a distinct intestinal expression pattern. Interest-
ingly, the stemness related gene, SOX2, is not expressed in
the wt cells, but strongly expressed upon CDX2 KO and
clearly decreased upon reinduction. This may suggest that
also stemness regulation is CDX2 dependent. The CDX2
targets identified in our data-set is to some extent in agree-
mentwith previous findings in a related cellular background
(38) (SupplementaryTable SI). Of note, the karyotype of the
LS174T cells used in our study was determined and found
to be in complete agreement with the originally near normal
published karyotype (41) (Supplementary Figure S9).
DISCUSSION
Gene regulatory mechanisms are complex and profit from
the development of systems in which gene and protein ex-
pression is tightly controlled. Tet-regulated expression sys-
tems have been widely used for inducible protein expression
inmammalian cells. However, current optimized Tet-on sys-
tems are still hampered by residual levels of gene expres-
sion in the uninduced state in both transiently and stably
transfected cells (18,21,22). We hereby demonstrate that the
PrIITE system resolves all issues related to leakiness and
importantly requires use of tetracycline dosages below cell
stress inducing concentrations (24). We first prove the PrI-
ITE concept using a Golgi targeted EYFP model reporter
(31). With this tightly controlled inducible reporter system
at hand, we were able to demonstrate, to the best of our
knowledge for the first time, that leakiness relates to in-
creased expression of the TET3G transactivator element
and not increased presence of the inducible GOI, in this
case the T2EYFP reporter, Supplementary Figure S10. We
furthermore show that stable random integrated pCMV-
TET3G transactivator elements causes leaky expression in
a substantial sub-population of the cells and we speculate
that this sub-population of cells enable uncontrolled Dox
induction levels beyond what is achievable in the tightly
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Figure 6. Identification and validation of the novel CDX2 target gene,GPA33. (A) Panel shows chromosome 1 coverage of CDX2ChIPseq reads (CDX2IP)
and control (input), calculated in 300 bp sliding windows as RPM (reads per million). For each window, input RPM was subtracted from CDX2IP RPM
and normalized values were saved as a bedgraph file for visualization in the UCSC Genome Browser. Major CDX2 binding sites (peaks) are shown with
indication of the GPA33 locus framed in red box. (B) Expanded display of the GPA33 locus, showing detailed identification of CDX2 ChIPSeq peaks
(ChIPseq/RPM) in both LS174T CDX2IP and control input samples. Major GPA33 CDX2 binding element is indicated by red triangle (CDX2 peak).
RNA-seq panel displays the density of individual reads in CDX2−/−2XindCDX2 with or without Dox induction (4 or 0 ng respectively) and LS174Twt
cells. RefSeq gene panel displays the genomic organization of neighboring genes in the GPA33 locus. (C) In vitro promoter analysis of the 0.6 kb CDX2
enhancer element identified in the GPA33 intron. pGL4-GPA33 and pGL4-GPA33enhancer represent the reporter plasmid without or with the enhancer
element included. Reporter expression is clearly dependent on both GPA33 CDX2 enhancer and CDX2 presence.
controlled PrIITE cells generated, Supplementary Figure
S10B. We next exemplify the potential of the system by
clarifying the role of CDX2 in intestinal cells as a con-
sequence of controlled CDX2 expression. This model sys-
tem shows that CDX2 predominantly acts as a transcrip-
tional activator and only a limited number of genes seemed
to be repressed by CDX2 presence, SOX2 being an exam-
ple hereof (Supplementary Table SII). We had anticipated
that CDX2 targeting in LS174T cells could become prob-
lematic due to its proposed essential cellular function and
pre-designed our targeting strategy for dealing with essen-
tial genes. This was accomplished by incorporating a ‘land-
ing pad’ in the EPB71 AAVS1 donor integration vector, just
downstream of the inducible gene of interest (Supplemen-
tary Figure S11). The ‘landing pad’ encodes the Safe Har-
bor #1 (SH1) sequence derived from the CHO genome, that
has successfully been utilized by us (51) and others (52) for
ZFNmediated target integration inCHO cells and thus rep-
resents a unique site when integrated in human cells devoid
of this sequence. This allows for subsequent donor target in-
tegration into the SH1 site. Establishment of a PrIITE cell
model for an essential gene can thus be accomplished, by
targeting of both the TET3G transactivator and inducible
pTRE3G codon optimizedGOI transcriptional elements to
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Figure 7. Global Dox induction reversibility of the PrIITE cells relative to LS174Twt cells. In order to include enough data points in the analysis, filtering
criteria included all genes with RPKM >1, that were 2× reduced in CDX2−/− KO cells and had a CDX2 binding element/peak in the gene locus. RNA-
seq data (RPKM) from wildtype LS174T was plotted against RPKM values from uninduced CDX2−/−2XindCDX2 cells without CDX2 expression (blue
dotted line, 2XindCDX 0 ng DOX) and under different conditions of CDX2/Dox induction (ng/ml) (green dotted line, 2XindCDX2 4 ng DOX; purple
dotted line, 1XindCDX2 4 ng DOX, red dotted line, 2XindCDX2 40 ng DOX). The regression line for each data set is plotted. The dark blue solid line
represents the expression levels in LS174Twt cells. (A) Global display of RNA-seq RPKM values for the samples analysed. RPKMs for the known CDX2
target genesMUC2 and TFF3 and the novel target gene,GPA33, are indicated by grey dotted vertical lines. Box with gray dotted line is area shown in panel
B. Representative examples of genes displaying full reversibility are indicated with arrow heads. (B) Zoom from dotted box from panel A with indication of
RPKM values for the novel CDX2 target gene, LDLR. Representative genes for which complete reversibility was observed are indicated by arrow heads.
(C) Global display of RNA-seq RPKMs for genes fulfilling the RPKM >1 and 2× reduction filtering criteria but without fulfilling the criteria of a CDX2
binding element/peak in the gene locus. Note the unordered dispersed display of RPKMs relative to the LS174Twt regression line, suggesting that a large
proportion of the CDX2 target genes only based on RNA-seq data are not direct targets of CDX2.
theAAVS1 locus, ex. byAAVS1 targeting of the former gene
followed by SH1 targeting of the later gene. Hereafter, pre-
cise target inactivation of the endogenous gene of interest in
the presence of Dox would ensure continued expression of
the inducible codon optimized version of the essential GOI.
In this project, we did not take advantage of this option,
since in the LS174T cellular model CDX2 has not proven
to act as a lineage-survival oncogene in contrast to what is
observed in other cell line models (40).
Our results also show that LS174T cells have a poor ca-
pacity to integrate homology arm flanked donor templates,
which is likely attributed to the lacking HR capacity of
these and other cell lines used (53–55). In general, precise
donor integration remains a challenge in the field and in
spite of the fact that CRISPR efficiently induces double
stranded breaks, CRISPR mediated donor integration im-
portantly comes at the expense of: (i) 3–20-fold higher indel
formation rates at the non-targeted allele (56,57) and (ii)
significant off-target/random integration frequencies (58).
These concerns were evident in a recent in vivo study based
on CRISPR target integration of inducible TRE3G pro-
moter elements, where ‘leaky’ expression in 33% of clones
analyzed was identified (59). In light of these CRISPR re-
lated issues, the ObLiGaRe targeting strategy by Marcello
Maresca et al. remains to be an efficient and reliable tar-
get integration strategy formost cells (60–63), includingHR
compromised cells such as CHO cells (64,65) and colorec-
tal cancer lines as described in this study and by Marcello
Maresca et al.
A whole set of novel genes, including GPA33 (44), LDLR
(66), MUC6, MUC5B and MUC5AC were identified as
CDX2 targets. To our knowledge, this has not previously
been demonstrated and suggests CDX2 as a locus control
gene of the 11p15 mucin gene cluster (67–69) that includes
MUC2, MUC6, MUC5B and MUC5AC. In this respect,
a recent study of 295 gastric adenocarcinomas has shown
that GPA33, MUC6 and MUC2 were among the 10 most
abundant differentially regulated genes in 295 analyzed mi-
crosatellite instable (MSI) colorectal adenocarcinomas (70).
Although CDX2 profiling was not evident in this study it
is stimulating to assume that MSI has impacted on CDX2
expression in the tumors studied. Furthermore, GPA33 is
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expressed in cancer of the gastrointestinal tract, namely in
over 95% of human colon cancers and has thus been sug-
gested as an attractive novel colorectal carcinoma therapeu-
tic target (71,72). Of particular notice, GPA33 gene product
has been shown to be post translationally modified by the
GALNT1 encoded GalNAc-transferase 1 enzyme (73,74),
that we here show is inversely influenced by CDX2 (Fig-
ure 5B). Our finding that LDLR is a major direct CDX2
target gene is surprising since LDLR has been primarily
found to be regulated by sterol regulated element-binding
proteins (SREBPs) (75,76). We speculate that CDX2 plays
novel roles in the co-regulated appearance of these novel
gene targets.
In summary, we hereby describe a novel approach for
generating an inducible ‘non leaky’ isogenic knockout-
rescue system. The principle is based on precise genome in-
tegration of defined copies of third generation Tet-On ele-
ments, which enables for an ‘all or none’ context for study-
ing themechanism by which a given gene works in a cell.We
exemplify the utility of the system by establishing a colonic
CDX2 PrIITE cell system that uncovered novel molecular
interactions governed by CDX2.
MATERIALS & CORRESPONDENCE
All reagents and cell lines used in the study are available
upon request for research purposes under a material trans-
fer agreement, except for TRE3G and TET3G contain-
ing plasmids, due to restrictions over distribution of plas-
mids containing the TRE3G promoter or TET3G ORF.
The RNA-seq and ChIP-seq data shown has been uploaded
at the NIH GEO server: http://www.ncbi.nlm.nih.gov/geo/
and is accessible using the following accession number
GSE97273. Plasmids described are available from Addgene
(https://www.addgene.org/). All correspondence should be
addressed to Eric P. Bennett.
NOTE ADDED IN PROOF
Extended experiments conducted during proofs of this
manuscript revealed that the GPA33 promoter described
in Figure 6 possess bi-directional transcriptional activity,
likely mediated through presence of multiple LINEs con-
tained within the 1KBp GPA33 promoter analyzed. LINEs
have been shown tomediate bi-directional expression (Trin-
klein, N.D., Aldred, S.F., Hartman, S.J., Schroeder, D.I.,
Otillar, R.P. and Myers, R.M. (2004) An abundance of
bidirectional promoters in the human genome. Genome
Res.14:62–66; Core, L.J.,Waterfall, J.J. and Core, J.T. (2008)
Nascent RNA sequencing reveals widespread pausing and
divergent initiation at human promoters. Science, 322:1845–
1848) potentially affecting 4% of all human genes (Speek,
M. (2001) Antisense promoter of human L1 retrotranspo-
son drives transcription of adjacent cellular genes. Mol.
Cell. Biol. 2001, 1973–1985; Criscione, S.W., Theodosakis,
N., Micevic, G., Cornish, T.C., Burns, K.H., Neretti, N.,
and Rodic´, N. (2016) Genome-wide characterization of hu-
manL1 antisense promoter-driven transcripts. BMC Ge-
nomics, 17:463).
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Supplementary Data are available at NAR Online.
ACKNOWLEDGEMENTS
We thank Camilla Andersen, Claire Katrine Beier Holden,
Asli Silahtaroglu, Elisabeth Larsen, Mads Bak (De-
partments of Odontology and Cellular and Molecular
Medicine, Copenhagen Center for Glycomics, University of
Copenhagen) and Katja Dahlgaard, (Department of Sci-
ence and Environment, Roskilde University, Denmark) for
excellent technical assistance. We thank Kim Madsen at
CLC Bioscience for guidance and access to CLC Work-
bench.
Author contributions: R.P. planned and performed all ZFN
targeting, IHC, FACS and live imaging experiments. L.H.,
M.C and C.M. planned and performed RNA-seq and
ChIPSeq experiments. S.L. and J.D. performed all in vitro
promoter analysis. J.B.H. performed Dox induction and
FACS experiments. J.T.T., R.A. and L.D. contributed
with writing parts of the manuscript. E.P.B. designed and
planned all experiments and wrote the manuscript.
FUNDING
University of Copenhagen Excellence Programme for In-
terdisciplinary Research [CDO2016]; The Danish Council
for Independent Research [4004-00140B], Novo Nordisk
Foundation, Danish National Research Foundation
[DNRF107], FEDER––Fundo Europeu de Desen-
volvimento Regional funds through the COMPETE
2020––Operacional Programme for Competitiveness and
Internationalisation (POCI), Portugal 2020; Portuguese
funds through FCT––Fundac¸a˜o para a Cieˆncia e a
Tecnologia/Ministe´rio da Cieˆncia, Tecnologia e Inovac¸a˜o
[POCI-01-0145-FEDER-007274, POCI-01-0145-FEDER-
016390]. Funding for open access charge: Danish National
Research Foundation [DNRF107].
Conflict of interest statement.None declared.
REFERENCES
1. McClintock,B. (1950) the origin and behavior of mutable loci in
maize. Proc. Natl. Acad. Sci. U.S.A., 36, 344–355.
2. Goth,R. and Rajewsky,M.F. (1972) Ethylation of nucleic acids by
ethylnitrosourea-l-14C fetal and adult Rat1. Cancer Res., 32,
1501–1505.
3. Hinton,C. and Whittinghill,M. (1950) The distribution of X-ray
induced crossovers from curly inversion heterozygotes of Drosophila
melanogaster females. Proc. Natl. Acad. Sci. U.S.A., 36, 552–558.
4. Capecchi,M.R. (1980) High efficiency transformation by direct
microinjection of DNA into cultured mammalian cells. Cell, 22,
479–488.
5. Mali,P., Yang,L., Esvelt,K.M., Aach,J., Guell,M., DiCarlo,J.E.,
Norville,J.E. and Church,G.M. (2013) RNA-guided human genome
engineering via Cas9. Science, 339, 823–826.
6. Cong,L., Ran,F.A., Cox,D., Lin,S., Barretto,R., Habib,N., Hsu,P.D.,
Wu,X., Jiang,W., Marraffini,L.a. et al. (2013) Multiplex genome
engineering using CRISPR/Cas systems. Science, 339, 819–823.
7. Geurts,A.M., Cost,G.J., Freyvert,Y., Zeitler,B., Jeffrey,C.,
Choi,V.M., Jenkins,S.S., Wood,A., Cui,X., Meng,X. et al. (2010)
Knockout rats produced using designed zinc finger nucleases.
Science, 325, 2009–2011.
8. Fire,A., Xu,S., Montgomery,M.K., Kostas,S.A., Driver,S.E. and
Mello,C.C. (1998) Potent and specific genetic interference by
Downloaded from https://academic.oup.com/nar/article-abstract/45/13/e123/3796334/Precise-integration-of-inducible-transcriptional
by Kobenhavns Universitets user
on 04 September 2017
e123 Nucleic Acids Research, 2017, Vol. 45, No. 13 PAGE 14 OF 15
double-stranded RNA in Caenorhabditis elegans. Nature, 391,
806–811.
9. Liu,J., Deutsch,U., Fung,I. and Lobe,C.G. (2014) Conditional and
inducible transgene expression in endothelial and hematopoietic cells
using Cre/loxP and tetracycline-off systems. Exp. Ther. Med., 8,
1351–1356.
10. Kuhn,R., Schwenk,F., Aguet,M. and Rajewsky,K. (1995) Inducible
gene targeting in mice. Science, 269, 1427–1428.
11. Braselmann,S., Graninger,P. and Busslinger,M. (1993) A selective
transcriptional induction system for mammalian cells based on
Gal4-estrogen receptor fusion proteins. Proc. Natl. Acad. Sci. U.S.A.,
90, 1657–1661.
12. Kennedy,M.J., Hughes,R.M., Peteya,L.A., Schwartz,J.W.,
Ehlers,M.D. and Tucker,C.L. (2010) Rapid blue-light – mediated
induction of protein interactions in living cells. Nat. Methods, 7,
12–16.
13. No,D., Yao,T.P. and Evans,R.M. (1996) Ecdysone-inducible gene
expression in mammalian cells and transgenic mice. Proc. Natl.
Acad. Sci. U.S.A., 93, 3346–3351.
14. Unger,B. and Hillen,W. (1984) Nucleotide sequence of the repressor
gene of the RAl tetracycline resistance determinant: structural and
functional comparison with three related Tet repressor genes
Bernhard. Nucleic Acids Res., 12, 7693–7703.
15. Postle,K., Nguyen,T.T. and Bertrand,K.P. (1984) Nucleic acids
research. Nucleic Acids Res., 12, 4849–4863.
16. Gossen,M. and Bujard,H. (1992) Tight control of gene expression in
mammalian cells by tetracycline-responsive promoters. Proc. Natl.
Acad. Sci. U.S.A., 89, 5547–5551.
17. Gossen,M., Freundlieb,S., Bender,G., Mu¨ller,G., Hillen,W. and
Bujard,H. (1995) Transcriptional activation by tetracyclines in
mammalian cells. Science, 268, 1766–1769.
18. Das,A.T., Zhou,X., Metz,S.W., Vink,M.A. and Berkhout,B. (2016)
Selecting the optimal Tet-On system for doxycycline-inducible gene
expression in transiently transfected and stably transduced
mammalian cells. Biotechnol. J., 11, 71–79.
19. Urlinger,S., Baron,U., Thellmann,M., Hasan,M.T., Bujard,H. and
Hillen,W. (2000) Exploring the sequence space for
tetracycline-dependent transcriptional activators: novel mutations
yield expanded range and sensitivity. Proc. Natl. Acad. Sci. U.S.A.,
97, 7963–7968.
20. Freundlieb,S., Schirra-Mu¨ller,C. and Bujard,H. (1999) A tetracycline
controlled activation/repression system with increased potential for
gene transfer into mammalian cells. J. Gene Med., 1, 4–12.
21. Loew,R., Heinz,N., Hampf,M., Bujard,H. and Gossen,M. (2010)
Improved Tet-responsive promoters with minimized background
expression. BMC Biotechnol., 10, 81.
22. Heinz,N., Schambach,A., Galla,M., Maetzig,T., Baum,C., Loew,R.
and Schiedlmeier,B. (2011) Retroviral and transposon-based
tet-regulated all-in-one vectors with reduced background expression
and improved dynamic range. Hum. Gene Ther., 22, 166–176.
23. Das,A.T., Liliane,T. and Berkhout,B. (2016) Tet-On systems for
doxycycline-inducible gene expression. Curr. Gene Ther., 16, 156–167.
24. Moullan,N., Mouchiroud,L., Houtkooper,R.H., Auwerx,J.,
Moullan,N., Mouchiroud,L., Wang,X., Ryu,D., Williams,E.G. and
Mottis,A. (2015) Tetracyclines disturb mitochondrial function across
eukaryotic models: a call for caution in biomedical article
tetracyclines disturb mitochondrial function across eukaryotic
models: a call for caution in biomedical research. Cell Rep., 10,
1681–1691.
25. Bensinger,S.J., Graeber,T.G. and Christofk,H.R. (2013) Doxycycline
alters metabolism and proliferation of human cell lines. PLoS One,
8, 8–14.
26. Bru¨ning,A., Brem,G.J., Vogel,M. and Mylonas,I. (2013)
Tetracyclines cause cell stress-dependent ATF4 activation and
mTOR inhibition. Exp. Cell Res., 320, 281–289.
27. Zhou,X., Vink,M., Klaver,B., Berkhout,B. and Das,A.T. (2006)
Optimization of the Tet-On system for regulated gene expression
through viral evolution. Gene Ther., 13, 1382–1390.
28. Suh,E., Chen,L., Taylor,J. and Traber,P.G. (1994) A homeodomain
protein related to caudal regulates intestine-specific gene
transcription.Mol. Cell. Biol., 14, 7340–7351.
29. Duda,K., Lonowski,L.a., Kofoed-Nielsen,M., Ibarra,A.,
Delay,C.M., Kang,Q., Yang,Z., Pruett-Miller,S.M., Bennett,E.P.,
Wandall,H.H. et al. (2014) High-efficiency genome editing via
2A-coupled co-expression of fluorescent proteins and zinc finger
nucleases or CRISPR/Cas9 nickase pairs. Nucleic Acids Res.,
doi:10.1093/nar/gku251.
30. Maresca,M., Lin,V.G., Guo,N. and Yang,Y. (2013) Obligate
Ligation-Gated Recombination (ObLiGaRe): custom-designed
nucleases mediated targeted integration through nonhomologous
end joining. Genome Res., doi:10.1101/gr.145441.112.
31. Wandall,H.H., Rumjantseva,V., Sørensen,A.L.T., Patel-Hett,S.,
Josefsson,E.C., Bennett,E.P., Italiono,J.E., Henrik,C., H,H.J. and
Hoffmeister,K.M. (2012) The origin and function of platelet
glycosyltransferases Glycosyltransferase assays Immunoblot analysis
Flow cytometric analysis of platelet glycosyltransferases. Blood, 120,
626–635.
32. Yang,Z., Steentoft,C., Hauge,C., Hansen,L., Thomsen,a. L.,
Niola,F., Vester-Christensen,M.B., Frodin,M., Clausen,H.,
Wandall,H.H. et al. (2015) Fast and sensitive detection of indels
induced by precise gene targeting. Nucleic Acids Res., 43, e59.
33. Lonowski,L.A., Narimatsu,Y., Riaz,A., Delay,C.E., Yang,Z.,
Niola,F., Duda,K., Ober,E.A., Clausen,H., Wandall,H.H. et al.
(2017) Genome editing using FACS enrichment of
nuclease-expressing cells and indel detection by amplicon analysis.
Nat. Protoc., 12, 581–603.
34. Coskun,M., Troelsen,J.T. and Nielsen,O.H. (2011) The role of CDX2
in intestinal homeostasis and inflammation. Biochim. Biophys. Acta,
1812, 283–289.
35. Ji,H., Jiang,H., Ma,W., Johnson,D.S., Myers,R.M. and Wong,W.H.
(2008) An integrated system CisGenome for analyzing ChIP-chip
and ChIP-seq data. Nat. Biotechnol., 26, 1293–1300.
36. Gao,N., White,P. and Kaestner,K.H. (2010) Establishment of
intestinal identity and epithelial-mesenchymal signaling by Cdx2.
Dev. Cell, 16, 588–599.
37. Mesquita,P., Jonckheere,N., Almeida,R., Ducourouble,M.P.,
Serpa,J., Silva,E., Pigny,P., Santos Silva,F., Reis,C., Silberg,D. et al.
(2003) Human MUC2 mucin gene is transcriptionally regulated by
Cdx homeodomain proteins in gastrointestinal carcinoma cell lines.
J. Biol. Chem., 278, 51549–51556.
38. Boyd,M., Hansen,M., Jensen,T.G.K., Perearnau,A., Olsen,A.K.,
Bram,L.L., Bak,M., Tommerup,N., Olsen,J. and Troelsen,J.T. (2010)
Genome-wide analysis of CDX2 binding in intestinal epithelial cells
(Caco-2). J. Biol. Chem., 285, 25115–25125.
39. Bennett,E.P., Mandel,U., Clausen,H., Gerken,T.a, Fritz,T.a and
Tabak,L.a (2012) Control of mucin-type O-glycosylation: a
classification of the polypeptide GalNAc-transferase gene family.
Glycobiology, 22, 736–756.
40. Salari,K., Spulak,M.E., Cuff,J., Forster,A.D., Giacomini,C.P. and
Huang,S. (2012) CDX2 is an amplified lineage-survival oncogene in
colorectal cancer Keyan. Proc. Natl. Acad. Sci. U.S.A., 109,
3196–3205.
41. Rutzky,L.P., Kaye,C.I., Siciliano,M.J., Chao,M. and Kahan,B.D.
(1980) Longitudinal karyotype and genetic signature analysis of
cultured human colon adenocarcinoma cell lines LS180 and LS174T.
Cancer Res., 40, 1443–1448.
42. Go¨ttke,M.S., Keller,K., Belley,A., Garcia,R.-M.,
Hollingsworth,M.A., Mack,D.R. and Chadee,K. (1998) Functional
heterogeneity of colonic adenocarcinoma mucins for inhibition of
Entamoeba histolytica adherence to target cells. J. Eukaryot.
Microbiol., 45, 17S–23S.
43. Bu,X.D., Li,N., Tian,X.Q. and Huang,P.L. (2011) Caco-2 and
LS174T cell lines provide different models for studying mucin
expression in colon cancer. Tissue Cell, 43, 201–206.
44. Heath,J.K., White,S.J., Johnstone,C.N., Catimel,B., Simpson,R.J.,
Moritz,R.L., Tu,G.F., Ji,H., Whitehead,R.H., Groenen,L.C. et al.
(1997) The human A33 antigen is a transmembrane glycoprotein and
a novel member of the immunoglobulin superfamily. Proc. Natl.
Acad. Sci. U.S.A., 94, 469–474.
45. Pinto,R., Barros,R., Pereira-Castro,I., Mesquita,P., da Costa,L.T.,
Bennett,E.P., Almeida,R. and David,L. (2015) CDX2 homeoprotein
is involved in the regulation of ST6GalNAc-I gene in intestinal
metaplasia. Lab. Invest., 95, 1–10.
46. Sakuma,K., Aoki,M. and Kannagi,R. (2012) Transcription factors
c-Myc and CDX2 mediate E-selectin ligand expression in colon
cancer cells undergoing EGF / bFGF-induced
epithelial––mesenchymal transition. Proc. Natl. Acad. Sci. U.S.A.,
109, 7776–7781.
Downloaded from https://academic.oup.com/nar/article-abstract/45/13/e123/3796334/Precise-integration-of-inducible-transcriptional
by Kobenhavns Universitets user
on 04 September 2017
PAGE 15 OF 15 Nucleic Acids Research, 2017, Vol. 45, No. 13 e123
47. Isshiki,S., Kudo,T., Nishihara,S., Ikehara,Y., Togayachi,A.,
Furuya,A., Shitara,K., Kubota,T., Watanabe,M., Kitajima,M. et al.
(2003) Lewis type 1 antigen synthase (3Gal-T5) is transcriptionally
regulated by homeoproteins. J. Biol. Chem., 278, 36611–36620.
48. Mitchelmore,C., Troelsen,J.T., Spodsberg,N., Sjo¨stro¨m,H. and
Nore´n,O. (2000) Interaction between the homeodomain proteins
Cdx2 and HNF1alpha mediates expression of the lactase-phlorizin
hydrolase gene. Biochem. J., 346, 529–535.
49. Hansen,L., Lind-thomsen,A., Joshi,H.J., Pedersen,N.B., Have,C.T.,
Kong,Y., Wang,S., Sparso,T., Grarup,N., Vester-christensen,M.B.
et al. (2015) A glycogene mutation map for discovery of diseases of
glycosylation. Glycobiology, 25, 211–224.
50. Rizzino,A. (2009) Sox2 and Oct-3/4: a versatile pair of master
regulators that orchestrate the self-renewal and pluripotency of
embryonic stem cells.Wiley Interdiscip. Rev. Syst. Biol. Med., 1,
228–236.
51. Yang,Z., Wang,S., Halim,A., Schulz,M.A., Frodin,M.,
Rahman,S.H., Vester-Christensen,M.B., Behrens,C., Kristensen,C.,
Vakhrushev,S.Y. et al. (2015) Engineered CHO cells for production
of diverse, homogeneous glycoproteins. Nat. Biotechnol.,
doi:10.1038/nbt.3280.
52. Bahr,S., Cortner,L., Ladley,S. and Borgschulte,T. (2013) Evaluating
the effect of chromosomal context on zinc finger nuclease efficiency.
BMC Proc., 7, P3.
53. Mansour,W.Y., Schumacher,S., Rosskopf,R., Rhein,T.,
Schmidt-Petersen,F., Gatzemeier,F., Haag,F., Borgmann,K.,
Willers,H. and Dahm-Daphi,J. (2008) Hierarchy of nonhomologous
end-joining, single-strand annealing and gene conversion at
site-directed DNA double-strand breaks. Nucleic Acids Res., 36,
4088–4098.
54. Cristea,S., Freyvert,Y., Santiago,Y., Holmes,M.C., Urnov,F.D.,
Gregory,P.D. and Cost,G.J. (2013) In vivo cleavage of transgene
donors promotes nuclease-mediated targeted integration. Biotechnol.
Bioeng., 110, 871–880.
55. Yang,Z., Wang,S., Halim,A., Schulz,M.A., Frodin,M.,
Rahman,S.H., Vester-christensen,M.B., Behrens,C., Kristensen,C.,
Vakhrushev,S.Y. et al. (2015) Engineered CHO cells for production of
diverse , homogeneous glycoproteins. Nat. Biotechnol., 33, 842–844.
56. Inui,M., Miyado,M., Igarashi,M., Tamano,M., Kubo,A.,
Yamashita,S., Asahara,H., Fukami,M. and Takada,S. (2014) Rapid
generation of mouse models with defined point mutations by the
CRISPR/Cas9 system. Sci. Rep., 4, 5396.
57. Lee,J.S., Grav,L.M., Pedersen,L.E., Lee,G.M. and Kildegaard,H.F.
(2016) Accelerated homology-directed targeted integration of
transgenes in Chinese hamster ovary cells via CRISPR/Cas9 and
fluorescent enrichment. Biotechnol. Bioeng., 9999, 1–17.
58. He,X., Tan,C., Wang,F., Wang,Y., Zhou,R., Cui,D., You,W.,
Zhao,H., Ren,J. and Feng,B. (2016) Knock-in of large reporter genes
in human cells via CRISPR/Cas9-induced homology-dependent and
independent DNA repair. Nucleic Acids Res., 44, e85.
59. Dow,L.E., Fisher,J., O’Rourke,K.P., Muley,A., Kastenhuber,E.R.,
Livshits,G., Tschaharganeh,D.F., Socci,N.D. and Lowe,S.W. (2015)
Inducible in vivo genome editing with CRISPR-Cas9. Nat.
Biotechnol., 33, 390–394.
60. Wang,J., Exline,C.M., DeClercq,J.J., Llewellyn,G.N., Hayward,S.B.,
Li,P.W.-L., Shivak,D.A., Surosky,R.T., Gregory,P.D., Holmes,M.C.
et al. (2015) Homology-driven genome editing in hematopoietic stem
and progenitor cells using ZFN mRNA and AAV6 donors. Nat.
Biotechnol., 33, 1256–1263.
61. Cai,Y., Laustsen,A., Zhou,Y., Sun,C., Anderson,M.V., Li,S.,
Uldbjerg,N., Luo,Y., Jakobsen,M.R. and Mikkelsen,J.G. (2016)
Targeted, homology-driven gene insertion in stem cells by
ZFN-loaded ‘ all-in-one ’ lentiviral vectors. Elife, e12213.
62. Coluccio,A., Miselli,F., Lombardo,A., Marconi,A., Malagoli
Tagliazucchi,G., Gonc¸alves,M.a, Pincelli,C., Maruggi,G., Del
Rio,M., Naldini,L. et al. (2013) Targeted gene addition in human
epithelial stem cells by zinc-finger nuclease-mediated homologous
recombination.Mol. Ther., 21, 1695–1704.
63. Moehle,E.a, Rock,J.M., Lee,Y.-L., Jouvenot,Y., DeKelver,R.C.,
Gregory,P.D., Urnov,F.D. and Holmes,M.C. (2007) Targeted gene
addition into a specified location in the human genome using
designed zinc finger nucleases. Proc. Natl. Acad. Sci. U.S.A., 104,
3055–3060.
64. Yamamoto,Y., Bliss,J. and Gerbi,S.A. (2015) Whole organism
genome editing: targeted large DNA insertion via ObLiGaRe
nonhomologous end-joining in vivo capture. G3 (Bethesda)., 5,
1843–1847.
65. Yang,Z., Wang,S., Halim,A., Schulz,M.A., Frodin,M.,
Rahman,S.H., Vester-Christensen,M.B., Behrens,C., Kristensen,C.,
Vakhrushev,S.Y. et al. (2015) Engineered CHO cells for production
of diverse, homogeneous glycoproteins. Nat. Biotechnol., 33,
2014–2017.
66. Brown,M.S., Goldstein,J.L., Arnold,W. and Perdue,S. (1974)
Expression of the familial hypercholesterolemia gene in
heterozygotes: mechanism for a dominant disorder in man. Science,
185, 61–63.
67. Van Cong,N., Aubert,J.P., Gross,M.S., Porchet,N., Degand,P. and
Fre´zal,J. (1990) Assignment of human tracheobronchial mucin
gene(s) to 11p15 and a tracheobronchial mucin-related sequence to
chromosome 13. Hum. Genet., 86, 167–172.
68. Gerard,C., Eddy,R.L. and Shows,T.B. (1990) The core polypeptide
of cystic fibrosis tracheal mucin contains a tandem repeat structure:
evidence for a common mucin in airway and gastrointestinal tissue. J.
Clin. Invest., 86, 1921–1927.
69. Velcich,A., Palumbo,L., Selleri,L., Evans,G. and Augenlicht,L.
(1997) Organization and regulatory aspects of the human intestinal
mucin gene (MUC2) locus. J. Biol. Chem., 272, 7968–7976.
70. Wheeler,D.a., Gibbs,R.a., Muzny,D.M., Bainbridge,M.N.,
Chang,K., Dinh,H.H., Drummond,J.a., Fowler,G., Kovar,C.L.,
Lewis,L.R. et al. (2012) Comprehensive molecular characterization
of human colon and rectal cancer. Nature, 487, 330–337.
71. Sakamoto,J., Kojima,H., Kato,J., Hamashima,H. and Suzuki,H.
(2000) Organ-specific expression of the intestinal epithelium-related
antigen A33, a cell surface target for antibody-based imaging and
treatment in gastrointestinal cancer. Cancer Chemother. Pharmacol.,
46(Suppl), S27–S32.
72. Ciprotti,M., Chong,G., Gan,H.K., Chan,A., Murone,C.,
MacGregor,D., Lee,F.-T., Johns,T.G., Heath,J.K., Ernst,M. et al.
(2014) Quantitative intratumoural microdistribution and kinetics of
(131)I-huA33 antibody in patients with colorectal carcinoma.
EJNMMI Res., 4, 1–10.
73. Steentoft,C., Vakhrushev,S.Y., Joshi,H.J., Kong,Y.,
Vester-Christensen,M.B., Schjoldager,K.T.-B.G., Lavrsen,K.,
Dabelsteen,S., Pedersen,N.B., Marcos-Silva,L. et al. (2013) Precision
mapping of the human O-GalNAc glycoproteome through
SimpleCell technology. EMBO J., 32, 1478–1488.
74. Kong,Y., Joshi,H.J., Schjoldager,K.T.-B.G., Madsen,T.D.,
Gerken,T.a, Vester-Christensen,M.B., Wandall,H.H., Bennett,E.P.,
Levery,S.B., Vakhrushev,S.Y. et al. (2014) Probing polypeptide
GalNAc-transferase isoform substrate specificities by in vitro
analysis. Glycobiology, 0, 1–11.
75. Horton,J.D., Goldstein,J.L. and Brown,M.S. (2002) SREBPs:
activators of the complete program of cholesterol and fatty acid
synthesis in the liver. J. Clin. Invest., 109, 1125–1131.
76. Shimano,H. (2001) Sterol regulatory element-binding proteins
(SREBPs): transcriptional regulators of lipid synthetic genes. Prog.
Lipid Res., 40, 439–452.
Downloaded from https://academic.oup.com/nar/article-abstract/45/13/e123/3796334/Precise-integration-of-inducible-transcriptional
by Kobenhavns Universitets user
on 04 September 2017
